Egypt's Minapharm lands up to $16.5M from CEPI for Ebola vaccine
What's the deal? Cairo-based MinapharmDealroom has a profile for this one. Try Dealroom → has secured up to $16.5 million from the Coalition for Epidemic PreparednessDealroom has a profile for this one. Try Dealroom → Innovations (CEPI) to develop an experimental Ebola vaccine. The grant will fund preclinical safety work and move the candidate toward clinical trials.
What's the endgame? The money supports Minapharm in optimising manufacturing processes and generating the preclinical safety data regulators require before human testing. The goal is a regionally produced countermeasure for a disease with case fatality rates that can reach 90%.
Why now? The deal expands vaccine manufacturing beyond traditional North American and European hubs. Public health agencies see locally produced countermeasures as central to containing outbreaks in high-risk regions.
What could go wrong? The candidate still faces standard clinical hurdles: establishing optimal dosage, evaluating immunogenicity, and monitoring for adverse events in randomised, double-blind, placebo-controlled trials. Trial designs must meet World Health Organization and other international standards, requiring high-containment biosafety infrastructure.
The signal: CEPI's investment reflects a broader shift toward decentralised vaccine production. By building local capacity for viral vectors and complex biologics, the initiative aims to cut supply chain vulnerabilities during future public health emergencies.
Read more: world-today-news.com
Image credit: US Army Africa
